Correction to: Prostate Cancer and Prostatic Diseases https://doi.org/10.1038/s41391-022-00555-0, published online 03 June 2022.
In Table 4 of this article, the data in the risk of MACE and composite CV events headed receiving more than 6 months of ADT were mistakenly listed under the headed preexisting CVD, receiving more than 6 months of ADT and vice versa.
The original article has been corrected.
Page 4: Last sentence before the section of Survival analysis.
In patients with pre-existing CVD and receiving ADT for ≥6 months, a 70% lower risk of composite CV events was determined in GnRH antagonisttreated patients than GnRHa-treated patients (aHR 0.30; 95% CI, 0.16–0.54; p < 0.0001; Table 4).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Shao, YH.J., Hong, JH., Chen, CK. et al. Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan. Prostate Cancer Prostatic Dis 26, 633–634 (2023). https://doi.org/10.1038/s41391-022-00596-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-022-00596-5
